{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:00:49Z","timestamp":1785517249608,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02267-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:12:53Z","timestamp":1785233573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["No-carrier-added 177Lu production eliminates persistent urine radioactivity: implications for safe expansion of targeted radionuclide therapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-2227","authenticated-orcid":false,"given":"Junichi","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Katsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukihide","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2267_CR1","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"2212","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. [177]Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;2212:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"2267_CR2","doi-asserted-by":"crossref","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021 Sept 16;385[12]:1091\u2013103.","DOI":"10.1056\/NEJMoa2107322"},{"key":"2267_CR3","doi-asserted-by":"crossref","unstructured":"Dash A, Pillai MRA, Knapp FF Jr. Production of [177]Lu for targeted radionuclide therapy: Available options. Nucl Med Mol Imaging [2010]. 2015 June;492:85\u2013107.","DOI":"10.1007\/s13139-014-0315-z"},{"key":"2267_CR4","doi-asserted-by":"crossref","unstructured":"Kondev FG, Ahmad I, Carpenter MP, Greene JP, Janssens RVF, Lauritsen T et al. Gamma-ray emission probabilities in the decay of (177m)Lu. Appl Radiat Isot. 2012 Sept 1;70[9]:1867\u201370.","DOI":"10.1016\/j.apradiso.2012.02.029"},{"key":"2267_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mednuc.2021.06.144","volume":"45","author":"D\u00e9marche d\u2019optimisation des modalit\u00e9s de gestion","year":"2021","unstructured":"D\u00e9marche d\u2019optimisation des modalit\u00e9s de gestion. des d\u00e9chets lors des traitements au 177Lu-oxodotr\u00e9otide (Lutathera\u00ae). M\u00e9decine Nucl\u00e9aire. 2021;45:263\u201370. [5\u20136].","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"key":"2267_CR6","doi-asserted-by":"crossref","unstructured":"Prevot S, Dyga\u00ef-Cochet I, Riedinger J-M, Vrigneaud J-M, Quermonne M, Gallet M et al. Dealing with dry waste disposal issues associated with 177mLu impurities: a long-term challenge for nuclear medicine departments. EJNMMI Phys. 2023;10[1]:3.","DOI":"10.1186\/s40658-023-00524-z"},{"key":"2267_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2174\/1874471008666150312161942","volume":"82","author":"A Dash","year":"2015","unstructured":"Dash A, Chakravarty R, Knapp FFR Jr, Pillai AMR. Indirect production of no carrier added (NCA) [177]Lu from irradiation of enriched [176]Yb: Options for ytterbium\/lutetium separation. Curr Radiopharm. 2015;82:107\u201318.","journal-title":"Curr Radiopharm"},{"issue":"2\u20133","key":"2267_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0969-8043(03)00158-1","volume":"59","author":"MRA Pillai","year":"2003","unstructured":"Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot. 2003;59(2\u20133):109\u201318.","journal-title":"Appl Radiat Isot"},{"key":"2267_CR9","unstructured":"Rubow S, le Roux J, Kleynhans J. Influence of the source of Lu-177 on radiopharmacy waste management \u2013 an estimate. In: Trends in Radiopharmaceuticals (ISTR-2019) Proceedings of an International Symposium Programme and Abstracts. 2020. pp. 190\u2013190."},{"key":"2267_CR10","unstructured":"Brinkevich S, Krot V, Brinkevich D, Ivaniykovich A. Long-lived radionuclidic impurities in the production of 18F-labelled radiopharmaceuticals. In: Trends in Radiopharmaceuticals (ISTR-2019) Proceedings of an International Symposium Programme and Abstracts. 2020. pp. 288\u2013288."},{"key":"2267_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7150\/thno.3645","volume":"25","author":"RP Baum","year":"2012","unstructured":"Baum RP, Kulkarni HR. THERANOSTICS: From molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy - the bad Berka experience. Theranostics. 2012;25:437\u201347.","journal-title":"Theranostics"},{"key":"2267_CR12","unstructured":"Management of radioactive waste from the use of radionuclides in medicine [Internet]. Vienna: International Atomic Energy Agency. 2000. Report No.: IAEA-TECDOC-1183. Available from: https:\/\/www-pub.iaea.org\/MTCD\/Publications\/PDF\/te_1183_prn.pdf"},{"issue":"1","key":"2267_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s41181-023-00222-2","volume":"8","author":"S Balzer","year":"2023","unstructured":"Balzer S, Breunig M, Kletting P, Glatting G, Vergara N, Beer AJ, et al. Evaluation of the \u00b9\u2077\u2077Lu-concentration in in-house produced \u00b9\u2077\u2077Lu-radiopharmaceuticals and commercially available Lutathera\u00ae. EJNMMI Radiopharmacy Chem. 2023;8(1):38.","journal-title":"EJNMMI Radiopharmacy Chem"},{"key":"2267_CR14","first-page":"976","volume":"567","author":"J Gustafsson","year":"2015","unstructured":"Gustafsson J, Sundl\u00f6v A, Sj\u00f6green Gleisner K. Long-Term Retention of \u00b9\u2077\u2077Lu\/\u00b9\u2077\u2077Lu-DOTATATE in Patients Investigated by \u03b3-Spectrometry and \u03b3-Camera Imaging. J Nucl Med. 2015;567:976\u201384.","journal-title":"J Nucl Med"},{"key":"2267_CR15","unstructured":"Lutathera\u00ae. (lutetium Lu 177 dotatate) [package insert]. Tokyo: Novartis Pharma K.K.; July 2025."}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02267-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02267-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:13:32Z","timestamp":1785514412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02267-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":15,"alternative-id":["2267"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02267-0","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}